Particularly, CD48, HAVCR2, LAG3, and TIGIT were identified as novel immunotherapeutic targets of several cancers [27–30], suggesting that the low-risk OS patients might benefit from their candidate inhibitors. Here, HAVCR2 is linked to cancer.